Watson’s Rozerem ANDA Prompts Takeda Suit

Takeda Pharmaceutical has sued Watson Pharmaceuticals over its ANDA for a generic version of Takeda’s insomnia treatment Rozerem. Takeda contends Watson’s claims that the ’239 patent on Rozerem (ramelteon) 8-mg tablets is invalid due to obviousness are baseless and seeks an injunction preventing the Watson drug from being sold before Rozerem’s patent expires, according to the suit filed in district court.
Generic Line